May 17, 2016
New Diagnostics Test and Technology for Hepatitis C
ABL inked an agreement with Inserm on a test and related IP and know-how intended for viral hepatitis C.
Read moreMay 17, 2016
ABL inked an agreement with Inserm on a test and related IP and know-how intended for viral hepatitis C.
Read moreApr 18, 2016
ABL is pleased to invite you to attend the viral typing webinar held with Thermo Fisher Scientific about the combination of their next generation sequencing systems and the ABL DeepChek downstream analysis software, for HIV, HBV and HCV. Tuesday, 10th May 2016 — 5 pm CET / 4 pm GMT / 11 am EST Regis…
Read moreMar 31, 2016
ABL inked a distribution agreement with Thermo Fisher Scientific for ViroScore and DeepChek, downstream analysis softwares for Sanger and Next Generation Sequencing respectively. These are also available on Thermo Fisher Cloud. See the press release.
Read moreJul 15, 2015
ABL group is pleased to announce the launch of an early access program (EAP) of its first genotyping DeepChek® assay for HCV NS5B. Further reagents will come soon to complete ABL Group’s offer for Sanger and Next Generation Sequencing. These reagents will be completed with data analysis software, Vi…
Read moreFeb 16, 2015
Barcelona, 16th February 2015. Researchers from Vall d’Hebron Research Institute (VHIR) have developed a new deep sequencing methodology that accurately classifies the 7 confirmed genotypes of the hepatitis C (HCV) virus, and the different subtypes. The new system also allows, for the first time, to…
Read moreJan 20, 2015
ABL is pleased to announce that its mark HepatiC® has now achieved registration with the United States Patent and Trademark Office on the Supplemental Register with N° 4,661,252. The HepatiC® software is a patient register to monitor HCV-infected patients in particular for ones using Direct Antivira…
Read moreJan 13, 2015
University Hospitals (UH) Case Medical Center has signed an agreement with Advanced Biological Laboratories (ABL), to join efforts on the designing and validation of an HIV drug resistance and tropism assay based on next-generation sequencing (NGS). See the press release. See the press release. http…
Read moreJan 05, 2015
Two new DeepChek® applications dedicated to viral hepatitis B (HBV) and hepatitis C (HCV) are now available in BaseSpace, the Illumina’s dedicated applications store and cloud-based informatics community dedicated to advancing genomic analysis. See the press release about BaseSpace and Illumina.
Read moreNov 17, 2014
ABL will be participating to the next Illumina BaseSpace Worldwide Developers Conference (WWDC) in San Francisco on the 8th and 9th of December 2014. View more
Read moreOct 22, 2014
ABL S.A, The University of Hong Kong and The Hong Kong Polytechnic University are launching their collaborative tuberculosis (TB) project to develop a deep-sequencing assay and its tailored bio-informatics pipeline. View more
Read moreOct 13, 2014
ABL is pleased to announce a new collaboration with the New Zealand Liver Transplant Unit and LabPlus at Auckland City Hospital. This will evaluate the susceptibility to develop Hepatocellular Carcinoma (HCC) during 30 years follow-up, based on key baseline genomic variations of HBV in a large cohor…
Read moreSep 02, 2014
ABL and Mayo Medical Laboratories will develop novel innovative LDT and related IT in the field of virology. More details available here.
Read moreAug 19, 2014
Advanced Biological Laboratories (ABL) and Roche Diagnostics International renew and extend their collaboration agreement to promote their Next-Generation Sequencing, Genotyping and Drug Resistance Products. See the full press release.
Read moreAug 19, 2014
First virology application on BaseSpace to deal with HIV next generation sequencing coming from Illumina’s platforms. See the press release about BaseSpace and Illumina.
Read moreJun 10, 2013